OA 03.04 A Phase II Study of Pembrolizumab for Patients with Refractory or Relapsed Thymic Epithelial Tumor

J. Cho,K. H. Yoo,H. Lee,H. K. Kim,Y. Kim,J. H. Cho,S. W. Lim,S. E. Park,J. Sun, S. Lee,J. S. Ahn, K. Park,M. Ahn

Journal of thoracic oncology（2017）

引用 0|浏览29

暂无评分

摘要

No standard treatment exists for patients with thymic epithelial tumor (TET) who progress after platinum-containing chemotherapy. We conducted a phase II study of pembrolizumab in patients with refractory or relapsed TET to evaluate the efficacy and safety.

查看译文

关键词

thymoma,thymic carcinoma,pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要